C07K 14/70521
Cd28, cd152
Official title: {cd28, cd152}
C07K14/70521 (Cd28, cd152) appears on 1,176 US grants and 2,473 published applications in this corpus.
Search patents in C07K- Granted patents
- 1,176
- Published applications
- 2,473
- Assignees
- 857
- Inventors
- 3,829
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 4 | 0 |
| 1997 | 3 | 0 |
| 1998 | 8 | 0 |
| 1999 | 11 | 0 |
| 2000 | 5 | 0 |
| 2001 | 2 | 1 |
| 2002 | 3 | 17 |
| 2003 | 7 | 23 |
| 2004 | 6 | 21 |
| 2005 | 7 | 10 |
| 2006 | 15 | 7 |
| 2007 | 20 | 10 |
| 2008 | 9 | 14 |
| 2009 | 10 | 20 |
| 2010 | 8 | 12 |
| 2011 | 5 | 21 |
| 2012 | 13 | 21 |
| 2013 | 17 | 26 |
| 2014 | 20 | 36 |
| 2015 | 14 | 42 |
| 2016 | 29 | 70 |
| 2017 | 30 | 98 |
| 2018 | 28 | 130 |
| 2019 | 66 | 187 |
| 2020 | 91 | 221 |
| 2021 | 104 | 312 |
| 2022 | 137 | 274 |
| 2023 | 111 | 255 |
| 2024 | 144 | 263 |
| 2025 | 144 | 215 |
| 2026 | 104 | 167 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Dual CAR expressing T cells individually linked to CD28 and 4-1BB6 Oct 2026US 12,753,218 B2The Trustees of the University of Pennsylvania
- Mesothelin specific chimeric antigen receptors (CAR) for solid tumors cancer immunotherapy6 Oct 2026US 12,753,220 B2Cellectis
- CD5 chimeric antigen receptor for adoptive T cell therapy29 Sep 2026US 12,746,273 B2Baylor College of Medicine
- Chimeric antigen receptor for treatment of cancer29 Sep 2026US 12,747,278 B2Industry-Academic Cooperation Foundation, Yonsei University
- Construction of chimeric antigen receptor targeting CD20 antigen and activity identification of engineered T cells thereof29 Sep 2026US 12,747,279 B2Abelzeta Inc.
- Cd28h domain-containing chimeric antigen receptors and methods of use8 Oct 2026US 2026/0306544 A1The United States of America, as represented by the Secretary, Dept. of Health and Human Services
- Chimeric receptors8 Oct 2026US 2026/0306631 A1St. Jude Children?S Research Hospital
- Nk cell compositions and preparations for immunotherapy and methods for their production8 Oct 2026US 2026/0308226 A1Deverra Therpaeutics Inc.
- Bispecific fusion proteins with immunosuppressive activity8 Oct 2026US 2026/0308227 A1
- Chimeric cytokine receptors and methods of use thereof1 Oct 2026US 2026/0294970 A1Legend Biotech USA Inc.
Most cited
By later US patents
- Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells512US 6,352,694 B1Genetics Institute, Inc. · 2002
- Methods for selectively stimulating proliferation of T cells452US 6,534,055 B1Genetics Institute, Inc. · 2003
- Nucleic acids encoding chimeric T cell receptors435US 7,446,190 B2Sloan-Kettering Institute for Cancer Research · 2008
- Methods of treating HIV infected subjects386US 6,905,680 B2Genetics Institute, Inc. · 2005
- Methods for selectively stimulating proliferation of T cells385US 6,887,466 B2Genetics Institute, Inc. · 2005